Authors

Latest:

Dr. Slamon on the Benefit of Ribociclib Plus Fulvestrant in HR+/HER2- Advanced Breast Cancer

Dennis J. Slamon, MD, PhD, discusses the long-term benefit of ribociclib plus fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer.

Dennis R. Scribner, MD

Latest:

Dr. Scribner on the Role of Chemotherapy in Ovarian Cancer

Dennis R. Scribner, MD, FACOG, FACS, clinical associate professor for the University of Arizona School of Medicine, Arizona Oncology, discusses the use of chemotherapy in patients with ovarian cancer.

Dennise Geiger, RN

Latest:

Dennise Geiger Discusses Telephone Triage in Cancer Care

Dennise Geiger, RN, Regional Cancer Care Associates, Central Jersey Division, discusses difficulties nurses face when using telephone triage, and the plan that was developed to better streamline the process.Â

denosumab-wins-drug-award

Latest:

Denosumab Wins Drug Award

At the 6th Annual Scrip Awards, featuring more than 500 representatives from the pharmaceutical industry, Amgen received the Best New Drug award for denosumab, the first approved inhibitor of RANK ligand.

Derek SantAngelo, PhD

Latest:

Dr. Sant'Angelo Explains Immunology Basics for Oncologists

Derek Sant'Angelo, PhD, Division Chief, Developmental Biology, Robert Wood Johnson Medical School, Dept. of Pediatrics, discusses what medical oncologists need to understand about immunology.

Deukwoo Kwon, PhD

Latest:

Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.

Devalingam Mahalingam, MD, PhD

Latest:

Autophagy Modulation May Be a Novel Approach to Treatment of Advanced Cancers

Although prolonged autophagy can result in cancer cell death, recent investigations suggest that therapy-induced autophagy is a reversible response that promotes cancer cell survival, and thus may diminish the efficacy of some therapeutic agents.

Devera Pine

Latest:

Bone-Targeted Therapies Evolve in Prostate Cancer

The treatment of bone metastases in prostate cancer has changed over the years, and several options are now either available or under development.

Devin C. Flaherty, DO, PhD

Latest:

Interdisciplinary Tumor Conferences: A Surgical Oncology Fellow's Review and Perspective

Devin C. Flaherty, DO, PhD, a surgical oncology fellow, discusses the evolution of interdisciplinary tumor board conferences and remarks on why they are so beneficial to the care of patients with cancer.

Dhanya K. Nambiar

Latest:

Combinations with Radiation for Head and Neck Cancer

Dhanya K. Nambiar, PhD, Stanford University, discusses combinations with radiation therapy for patients with head and neck cancer.

Dhanya K. Nambiar, PhD

Latest:

The Detection of Galectin-1 in Head and Neck Cancer

Dhanya K. Nambiar, PhD, Stanford University, discusses the detection of Galectin-1 for patients with head and neck cancer.

Dhanya K. Nambier, PhD

Latest:

The Development of Galectin-1 for Head and Neck Cancer

Dhanya K. Nambiar, PhD, Stanford University, discusses the importance of continuing to study Galectin-1 for patients with head and neck cancer.

Dhaval Shah, MD

Latest:

Planning Ahead for a Career

The 3 years of my fellowship training were a life-changing experience that will stay with me forever.

Dialecti Voudouris, MD

Dian Wang, MD

Latest:

Radiation Therapy, Chemotherapy, Targeted Therapy, and Possibly Immunotherapy in Localized Sarcoma

As clinicians have gained an improved understanding of the biology of soft-tissue sarcoma malignancies, the ability to better distinguish and identify subtypes has extended the hope of targeted treatment options.

Diana Osorio, MD

Latest:

Providing Oncology Services in Impoverished Countries

Many of us training in the United States have encountered patients and their families from resource-limited regions of the world-families who have uprooted themselves for the chance to save the lives of their children diagnosed with cancer.

Diana P. English, MD

Latest:

Dr. English on an Investigational Antibody-Drug Conjugate in Ovarian Cancer

Diana P. English, MD, a gynecologic oncologist at Stanford Hospital and Clinics, discusses an investigational antibody-drug conjugate (ADC) in ovarian cancer.

Diana Verrilli

Latest:

Top 3 Must Do's to Prepare for Managed Care in 2016

Although there still are many unknowns, especially in light of this being an election year that will bring a new administration, itâ€™s already very clear how the transition to value is affecting oncology practices.

Diana Verrilli, MS

Latest:

Moving to Electronic Prior Authorization Requires Incremental Steps

In a time of tremendous technological advancement, how is it that 90% of communications between providers and payers for prior authorizations are still done by phone or fax, and how do we move to more automated processes?1

Diane C. Bodurka, MD

Latest:

Dr. Bodurka on the Increasing Number of Cancer Survivors

Dr. Diane Bodurka, from the MD Anderson Cancer Center, on the Increasing Number of Cancer Surivors